Dr. Sudhir Manda
Claim this profileArizona Oncology Associates
About Sudhir Manda
Education:
- Obtained MD from the University of Arizona College of Medicine, Tucson, AZ.
- Completed Residency in Internal Medicine at the University of Arizona College of Medicine, Tucson, AZ.
- Undertook Fellowship in Hematology/Oncology at the University of Arizona Cancer Center, Tucson, AZ.
Experience:
- Board-certified in Internal Medicine, Hematology, and Medical Oncology.
- Associated with Arizona Oncology Associates.
Area of expertise
Lymphoma
Sudhir Manda has run 5 trials for Lymphoma. Some of their research focus areas include:
B-Cell Lymphoma
Sudhir Manda has run 4 trials for B-Cell Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Arizona Oncology Associates
Arizona Oncology Associates, PC - HOPE
Clinical Trials Sudhir Manda is currently running
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting
1 award
Phase 3
4 criteria
Selinexor + R-GDP
for Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.
Recruiting
0 awards
Phase 2 & 3
9 criteria
More about Sudhir Manda
Clinical Trial Related
5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Sudhir Manda has experience with
- Lenalidomide
- Rituximab
- Pembrolizumab
- Dexamethasone
- Gemcitabine
- Selinexor
Breakdown of trials Sudhir Manda has run
Lymphoma
B-Cell Lymphoma
Colorectal Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sudhir Manda specialize in?
Sudhir Manda focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved metastatic patients, or patients who are RECIST 1.1.
Is Sudhir Manda currently recruiting for clinical trials?
Yes, Sudhir Manda is currently recruiting for 2 clinical trials in Tucson Arizona. If you're interested in participating, you should apply.
Are there any treatments that Sudhir Manda has studied deeply?
Yes, Sudhir Manda has studied treatments such as Lenalidomide, Rituximab, Pembrolizumab.
What is the best way to schedule an appointment with Sudhir Manda?
Apply for one of the trials that Sudhir Manda is conducting.
What is the office address of Sudhir Manda?
The office of Sudhir Manda is located at: Arizona Oncology Associates, Tucson, Arizona 85711 United States. This is the address for their practice at the Arizona Oncology Associates.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.